Switch Therapeutics
在场
高管
生物技术
Switch Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Switch Therapeutics 的最新新闻稿
- Switch Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference | Switch Therapeutics
- Eight biotech companies advancing the field of siRNA
- Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference | Switch Therapeutics
- Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer | Switch Therapeutics
- Switch Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference | Switch Therapeutics
- Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors | Switch Therapeutics
- Switch Therapeutics Announces Formation of Scientific Advisory Board | Switch Therapeutics
- Switch Therapeutics Expands Leadership Team with Key Appointments | Switch Therapeutics
- Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology | Switch Therapeutics
- Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’ | Switch Therapeutics
- View more press releases Close
通过电子邮件
